ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
30. Juni 2016 07:00 ET
|
ArQule, Inc.
75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations BURLINGTON, Mass., June 30, 2016 (GLOBE NEWSWIRE) --...
ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
23. Juni 2016 07:00 ET
|
ArQule, Inc.
BURLINGTON, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in intrahepatic...
ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087
15. Dezember 2015 07:30 ET
|
ArQule, Inc.
Orphan drug designation marks significant regulatory milestone for phase 2 trialAdditional response in phase 1b further validates development for ARQ 087 in cancers with FGFR2 genetic alterations ...
UPDATE -- ArQule Presents Data on Tivantinib and Proprietary Pipeline at AACR-NCI-EORTC Conference
09. November 2015 07:55 ET
|
ArQule, Inc.
Data connects preclinical and clinical studies validating ArQule’s precision medicine strategy BURLINGTON, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the...
ArQule Presents Data on Tivantinib and Propietary Pipeline at AACR-NCI-EORTC Conference
09. November 2015 07:30 ET
|
ArQule, Inc.
Data connects preclinical and clinical studies validating ArQule’s precision medicine strategy BURLINGTON, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the...
ArQule to Present Data on Tivantinib, ARQ 087, ARQ 092, and ARQ 751 at AACR-NCI-EORTC Conference
27. Oktober 2015 07:30 ET
|
ArQule, Inc.
Single-agent and combination pre-clinical and clinical data supportive of on-going clinical trials BURLINGTON, Mass., Oct. 27, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced...